Pharmacophore and three-dimensional quantitative structure activity relationship methods for modeling cytochrome p450 active sites.
暂无分享,去创建一个
S. Ekins | M. D. de Groot | J. Jones | M J de Groot | J P Jones | S Ekins | Sean Ekins | Marcel J. de Groot | Jeffrey P. Jones
[1] N. Vermeulen,et al. Computer prediction and experimental validation of cytochrome P4502D6-dependent oxidation of GBR 12909. , 1995, Drug metabolism and disposition: the biological fate of chemicals.
[2] C Masimirembwa,et al. Arginines 97 and 108 in CYP2C9 are important determinants of the catalytic function. , 2000, Biochemical and biophysical research communications.
[3] T. Shimizu,et al. Potentiation of anticoagulant effect of warfarin caused by enantioselective metabolic inhibition by the uricosuric agent benzbromarone , 1999, Clinical pharmacology and therapeutics.
[4] D. Lewis,et al. On the recognition of mammalian microsomal cytochrome P450 substrates and their characteristics: towards the prediction of human p450 substrate specificity and metabolism. , 2000, Biochemical pharmacology.
[5] Gabriele Cruciani,et al. Three-Dimensional Quantitative Structure-Properties Relationships , 2003 .
[6] J. Halpert,et al. Molecular basis of P450 inhibition and activation: implications for drug development and drug therapy. , 1998, Drug metabolism and disposition: the biological fate of chemicals.
[7] Robert L. Haining,et al. Enzymatic Determinants of the Substrate Specificity of CYP2C9: Role of B‘−C Loop Residues in Providing the π-Stacking Anchor Site for Warfarin Binding† , 1999 .
[8] Ferran Sanz,et al. THEORETICAL STUDY ON THE METABOLISM OF CAFFEINE BY CYTOCHROME P-450 1A2 AND ITS INHIBITION , 1994 .
[9] J. Idle,et al. The cytochrome P450 CYP2D6 allelic variant CYP2D6J and related polymorphisms in a European population. , 1994, Pharmacogenetics.
[10] C Skoda,et al. The molecular mechanisms of two common polymorphisms of drug oxidation--evidence for functional changes in cytochrome P-450 isozymes catalysing bufuralol and mephenytoin oxidation. , 1986, Xenobiotica; the fate of foreign compounds in biological systems.
[11] S. Ekins,et al. Three-dimensional quantitative structure activity relationship analyses of substrates for CYP2B6. , 1999, The Journal of pharmacology and experimental therapeutics.
[12] S. Ekins,et al. Progress in predicting human ADME parameters in silico. , 2000, Journal of pharmacological and toxicological methods.
[13] M H Tarbit,et al. Molecular modelling of lanosterol 14 alpha-demethylase (CYP51) from Saccharomyces cerevisiae via homology with CYP102, a unique bacterial cytochrome P450 isoform: quantitative structure-activity relationships (QSARs) within two related series of antifungal azole derivatives. , 1999, Journal of enzyme inhibition.
[14] L. Moore,et al. St. John's wort induces hepatic drug metabolism through activation of the pregnane X receptor. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[15] György G. Ferenczy,et al. The active site of cytochrome P-450 nifedipine oxidase: a model-building study. , 1989, Journal of molecular graphics.
[16] C. Hansch,et al. QSAR of P450 oxidation: on the value of comparing kcat and km with kcat/km. , 1996, Drug metabolism reviews.
[17] Francesca Fanelli,et al. Theoretical investigation of substrate specificity for cytochromes P450 IA2, P450 IID6 and P450 IIIA4 , 2000, J. Comput. Aided Mol. Des..
[18] D. Mansuy,et al. Interaction of sulfaphenazole derivatives with human liver cytochromes P450 2C: molecular origin of the specific inhibitory effects of sulfaphenazole on CYP 2C9 and consequences for the substrate binding site topology of CYP 2C9. , 1996, Biochemistry.
[19] Wannian Zhang,et al. A three-dimensional model of lanosterol 14α-demethylase of Candida albicans , 1998 .
[20] A. Parkinson,et al. Inhibition of coumarin 7-hydroxylase activity in human liver microsomes. , 1997, Archives of biochemistry and biophysics.
[21] C. Hansch,et al. Quantitative structure-activity relationships of cytochrome P-450. , 1993, Drug metabolism reviews.
[22] M H Tarbit,et al. Molecular modelling of CYP3A4 from an alignment with CYP102: identification of key interactions between putative active site residues and CYP3A-specific chemicals. , 1996, Xenobiotica; the fate of foreign compounds in biological systems.
[23] F. Guengerich,et al. Development of a pharmacophore for inhibition of human liver cytochrome P-450 2D6: molecular modeling and inhibition studies. , 1993, Journal of medicinal chemistry.
[24] M. van den Berg,et al. Structure-dependent induction of CYP1A by polychlorinated biphenyls in hepatocytes of cynomolgus monkeys (Macaca fascicularis). , 1999, Toxicology and applied pharmacology.
[25] Vithal M. Kulkarni,et al. Development of Pharmacophore Alignment Models as Input for Comparative Molecular Field Analysis of a Diverse Set of Azole Antifungal Agents , 1999, J. Chem. Inf. Comput. Sci..
[26] R. Cramer,et al. Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. , 1988, Journal of the American Chemical Society.
[27] S. Horvat,et al. Characterization of the mouse lanosterol 14alpha-demethylase (CYP51), a new member of the evolutionarily most conserved cytochrome P450 family. , 2000, Archives of biochemistry and biophysics.
[28] P. Ortiz de Montellano,et al. Active site topology of human cytochrome P450 2E1. , 1996, Chemical research in toxicology.
[29] D. Mansuy,et al. The substrate binding site of human liver cytochrome P450 2C9: an approach using designed tienilic acid derivatives and molecular modeling. , 1995, Biochemistry.
[30] S. Grimm,et al. Inhibition of human drug metabolizing cytochromes P450 by anastrozole, a potent and selective inhibitor of aromatase. , 1997, Drug metabolism and disposition: the biological fate of chemicals.
[31] D. Lewis,et al. Quantitative structure-activity relationships in substrates, inducers, and inhibitors of cytochrome P4501 (CYP1). , 1997, Drug metabolism reviews.
[32] J. Venhorst,et al. Design, synthesis, and characterization of 7-methoxy-4-(aminomethyl)coumarin as a novel and selective cytochrome P450 2D6 substrate suitable for high-throughput screening. , 1999, Chemical research in toxicology.
[33] S. Wrighton,et al. The human hepatic cytochromes P450 involved in drug metabolism. , 1992, Critical reviews in toxicology.
[34] C. Hansch. Quantitative Relationships Between Lipophilic Character and Drug Metabolism , 1972 .
[35] B C Finzel,et al. Crystal structure of substrate-free Pseudomonas putida cytochrome P-450. , 1986, Biochemistry.
[36] W. Legrum,et al. Approach to Detect Substrates Suitable to Measure the Coumarin 7‐Hydroxylase (Cyp 2a‐5) ‐ Structure‐Activity Relationships , 1994, Archiv der Pharmazie.
[37] J. Idle,et al. POLYMORPHIC HYDROXYLATION OF DEBRISOQUINE IN MAN , 1977, The Lancet.
[38] Barry C. Jones,et al. Properties of cytochrome P450 isoenzymes and their substrates Part 1: active site characteristics , 1997 .
[39] M. Waterman,et al. Characterization and catalytic properties of the sterol 14alpha-demethylase from Mycobacterium tuberculosis. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[40] J. Miners,et al. Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. , 1998, British journal of clinical pharmacology.
[41] S A van Acker,et al. A predictive model for substrates of cytochrome P450-debrisoquine (2D6). , 1992, Chemical research in toxicology.
[42] Vithal M. Kulkarni,et al. Three-Dimensional Quantitative Structure-Activity Relationship (QSAR) and Receptor Mapping of Cytochrome P-45014DM Inhibiting Azole Antifungal Agents1 , 1999, J. Chem. Inf. Comput. Sci..
[43] S. Ekins,et al. Three and four dimensional-quantitative structure activity relationship (3D/4D-QSAR) analyses of CYP2D6 inhibitors. , 1999, Pharmacogenetics.
[44] N. Vermeulen,et al. A refined substrate model for human cytochrome P450 2D6. , 1997, Chemical research in toxicology.
[45] J. Lehmann,et al. An Orphan Nuclear Receptor Activated by Pregnanes Defines a Novel Steroid Signaling Pathway , 1998, Cell.
[46] Maurizio Recanatini,et al. Comparative molecular field analysis of non-steroidal aromatase inhibitors related to fadrozole , 1996, J. Comput. Aided Mol. Des..
[47] P. Maurel,et al. Metabolism of the new immunosuppressor cyclosporin G by human liver cytochromes P450. , 1996, Biochemical pharmacology.
[48] J. G. Snijders,et al. Extension of a predictive substrate model for human cytochrome P4502D6. , 1997, Xenobiotica; the fate of foreign compounds in biological systems.
[49] D A Smith,et al. Speculations on the substrate structure-activity relationship (SSAR) of cytochrome P450 enzymes. , 1992, Biochemical pharmacology.
[50] Jon A. Erickson,et al. A comparative molecular field analysis study of obtusifoliol 14α-methyl demethylase inhibitors † , 1999 .
[51] F. Sanz,et al. Quinolone antibacterial agents: relationship between structure and in vitro inhibition of the human cytochrome P450 isoform CYP1A2. , 1993, Molecular pharmacology.
[52] C. Hansch,et al. Structure--activity correlations in the metabolism of drugs. , 1968, Archives of biochemistry and biophysics.
[53] A. Alex,et al. Novel approach to predicting P450-mediated drug metabolism: development of a combined protein and pharmacophore model for CYP2D6. , 1999, Journal of medicinal chemistry.
[54] D. Lewis,et al. Molecular modelling and quantitative structure-activity relationship studies on the interaction of omeprazole with cytochrome P450 isozymes. , 1998, Toxicology.
[55] Eric F. Johnson,et al. Engineering Microsomal Cytochrome P450 2C5 to Be a Soluble, Monomeric Enzyme , 2000, The Journal of Biological Chemistry.
[56] Antti Poso,et al. A comparative molecular field analysis of cytochrome P450 2A5 and 2A6 inhibitors , 2001, J. Comput. Aided Mol. Des..
[57] T Ishizaki,et al. Metabolic interactions of selected antimalarial and non-antimalarial drugs with the major pathway (3-hydroxylation) of quinine in human liver microsomes. , 2003, British journal of clinical pharmacology.
[58] M H Tarbit,et al. Structural determinants of cytochrome P450 substrate specificity, binding affinity and catalytic rate. , 1998, Chemico-biological interactions.
[59] T. Theophanides,et al. Molecular modeling of azole antifungal agents active against Candida albicans. 1. A comparative molecular field analysis study. , 1996, Journal of medicinal chemistry.
[60] G. Szklarz,et al. Molecular modeling of mammalian cytochromes P450: application to study enzyme function. , 2000, Vitamins and hormones.
[61] Wannian Zhang,et al. A three-dimensional model of lanosterol 14alpha-demethylase of Candida albicans and its interaction with azole antifungals. , 2000, Journal of medicinal chemistry.
[62] D A Smith,et al. Putative active site template model for cytochrome P4502C9 (tolbutamide hydroxylase). , 1996, Drug metabolism and disposition: the biological fate of chemicals.
[63] S. Loft,et al. Fluvoxamine is a potent inhibitor of cytochrome P4501A2. , 1993, Biochemical pharmacology.
[64] N. Vermeulen,et al. Modeling the active sites of cytochrome P450s and glutathione S-transferases, two of the most important biotransformation enzymes. , 1997, Drug metabolism reviews.
[65] D E McRee,et al. Mammalian microsomal cytochrome P450 monooxygenase: structural adaptations for membrane binding and functional diversity. , 2000, Molecular cell.
[66] G. Tucker,et al. Regioselective hydroxylation of debrisoquine by cytochrome P4502D6: implications for active site modelling , 2000, Xenobiotica; the fate of foreign compounds in biological systems.
[67] Jeffrey P. Jones,et al. Three-dimensional quantitative structure-activity relationship for inhibitors of cytochrome P4502C9. , 1996, Drug metabolism and disposition: the biological fate of chemicals.
[68] Tudor I. Oprea,et al. Three-dimensional quantitative structure-activity relationships of steroid aromatase inhibitors , 1996, J. Comput. Aided Mol. Des..
[69] W. Trager,et al. Enzymatic determinants of the substrate specificity of CYP2C9: role of B'-C loop residues in providing the pi-stacking anchor site for warfarin binding. , 1999, Biochemistry.
[70] G. Nelsestuen,et al. Steady state enzyme velocities that are independent of [enzyme]: an important behavior in many membrane and particle-bound states. , 1997, Biochemistry.
[71] A. Alex,et al. A novel approach to predicting P450 mediated drug metabolism. CYP2D6 catalyzed N-dealkylation reactions and qualitative metabolite predictions using a combined protein and pharmacophore model for CYP2D6. , 1999, Journal of medicinal chemistry.
[72] Jeffrey P. Jones,et al. A refined 3-dimensional QSAR of cytochrome P450 2C9: computational predictions of drug interactions. , 2000, Journal of medicinal chemistry.
[73] J. Lehmann,et al. The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. , 1998, The Journal of clinical investigation.
[74] M H Tarbit,et al. Molecular modelling of CYP2B6, the human CYP2B isoform, by homology with the substrate-bound CYP102 crystal structure: evaluation of CYP2B6 substrate characteristics, the cytochrome b5 binding site and comparisons with CYP2B1 and CYP2B4. , 1999, Xenobiotica; the fate of foreign compounds in biological systems.
[75] T. Fujita. Recent Success Stories Leading to Commercializable Bioactive Compounds with the Aid of Traditional QSAR Procedures , 1997 .
[76] Jeffrey P. Jones,et al. Structural forms of phenprocoumon and warfarin that are metabolized at the active site of CYP2C9. , 1999, Archives of biochemistry and biophysics.
[77] Dennis A. Smith,et al. Properties of cytochrome P450 isoenzymes and their substrates Part 2: properties of cytochrome P450 substrates , 1997 .
[78] C. Waller,et al. Modeling the cytochrome P450-mediated metabolism of chlorinated volatile organic compounds. , 1996, Drug metabolism and disposition: the biological fate of chemicals.
[79] F. Guengerich,et al. Substrate specificity of human liver cytochrome P-450 debrisoquine 4-hydroxylase probed using immunochemical inhibition and chemical modeling. , 1985, Cancer research.
[80] J Guillon,et al. New aromatase inhibitors. Synthesis and biological activity of aryl-substituted pyrrolizine and indolizine derivatives. , 2000, Bioorganic & medicinal chemistry.
[81] S. Ekins,et al. Three- and four-dimensional-quantitative structure activity relationship (3D/4D-QSAR) analyses of CYP2C9 inhibitors. , 2000, Drug metabolism and disposition: the biological fate of chemicals.
[82] O. Gotoh,et al. Sterol 14-demethylase P450 (CYP51) provides a breakthrough for the discussion on the evolution of cytochrome P450 gene superfamily. , 2000, Biochemical and biophysical research communications.
[83] M J Sternberg,et al. A three-dimensional molecular template for substrates of human cytochrome P450 involved in debrisoquine 4-hydroxylation. , 1991, Carcinogenesis.
[84] C. Yoon,et al. Structure-related inhibition of human hepatic caffeine N3-demethylation by naturally occurring flavonoids. , 1998, Biochemical pharmacology.
[85] N. Vermeulen,et al. A three-dimensional protein model for human cytochrome P450 2D6 based on the crystal structures of P450 101, P450 102, and P450 108. , 1996, Chemical research in toxicology.
[86] T. Sueyoshi,et al. The Nuclear Orphan Receptor CAR-Retinoid X Receptor Heterodimer Activates the Phenobarbital-Responsive Enhancer Module of the CYP2B Gene , 1998, Molecular and Cellular Biology.
[87] D. Kelly,et al. Characteristics of the heterologously expressed human lanosterol 14α‐demethylase (other names: P45014DM, CYP51, P45051) and inhibition of the purified human and Candida albicans CYP51 with azole antifungal agents , 1999, Yeast.
[88] S. Ekins,et al. Three-dimensional-quantitative structure activity relationship analysis of cytochrome P-450 3A4 substrates. , 1999, The Journal of pharmacology and experimental therapeutics.
[89] M. Pincus,et al. Molecular modeling of mammalian cytochrome P450s , 2000, Cellular and Molecular Life Sciences CMLS.
[90] M. Kirby,et al. Fallen arches, or how the vertebrate got its head. , 1998, The Journal of clinical investigation.
[91] B C Finzel,et al. The 2.6-A crystal structure of Pseudomonas putida cytochrome P-450. , 1985, The Journal of biological chemistry.
[92] P. Maurel,et al. Cyclosporin A drug interactions. Screening for inducers and inhibitors of cytochrome P-450 (cyclosporin A oxidase) in primary cultures of human hepatocytes and in liver microsomes. , 1990, Drug metabolism and disposition: the biological fate of chemicals.
[93] Ferran Sanz,et al. 3D-QSAR methods on the basis of ligand–receptor complexes. Application of COMBINE and GRID/GOLPE methodologies to a series of CYP1A2 ligands , 2000, J. Comput. Aided Mol. Des..
[94] Z. Simon,et al. Theoretical Investigations on the Role of Steroid-Skeleton C4 = C5 Unsaturation in Competitive Aromatase Inhibition , 1989, Zeitschrift fur Naturforschung. C, Journal of biosciences.
[95] Grazyna D. Szklarz,et al. Molecular modeling of cytochrome P450 3A4 , 1997, J. Comput. Aided Mol. Des..
[96] Antti Poso,et al. Comparative Molecular Field Analysis of Compounds with CYP2A5 Binding Affinity , 1995 .
[97] S. Ekins,et al. The role of CYP2B6 in human xenobiotic metabolism. , 1999, Drug metabolism reviews.
[98] Gianpaolo Bravi,et al. Application of MS‐WHIM Descriptors: 1. Introduction of New Molecular Surface Properties and 2. Prediction of Binding Affinity Data , 2000 .
[99] Anton J. Hopfinger,et al. Molecular Shape and QSAR Analyses of a Family of Substituted Dichlorodiphenyl Aromatase Inhibitors , 1994, J. Chem. Inf. Comput. Sci..
[100] A. Cavalli,et al. Comparative molecular field analysis of non-steroidal aromatase inhibitors: an extended model for two different structural classes. , 1998, Bioorganic & medicinal chemistry.
[101] D. Lewis,et al. Structural characteristics of human P450s involved in drug metabolism: QSARs and lipophilicity profiles. , 2000, Toxicology.
[102] S. Ekins,et al. Three- and four-dimensional quantitative structure activity relationship analyses of cytochrome P-450 3A4 inhibitors. , 1999, The Journal of pharmacology and experimental therapeutics.
[103] V. Kulkarni,et al. Three‐Dimensional Quantitative Structure—Activity Relationship (QSAR) and Receptor Mapping of Cytochrome P‐45014αDM Inhibiting Azole Antifungal Agents. , 1999 .
[104] K. Chiba,et al. Inhibitory effects of antiarrhythmic drugs on phenacetin O-deethylation catalysed by human CYP1A2. , 1998, British journal of clinical pharmacology.
[105] J. Halpert,et al. Use of homology modeling in conjunction with site-directed mutagenesis for analysis of structure-function relationships of mammalian cytochromes P450. , 1997, Life sciences.
[106] J. Venhorst,et al. Influence of N-substitution of 7-methoxy-4-(aminomethyl)-coumarin on cytochrome P450 metabolism and selectivity. , 2000, Drug metabolism and disposition: the biological fate of chemicals.
[107] P. Ortiz de Montellano,et al. Active site topology of Saccharomyces cerevisiae lanosterol 14 alpha-demethylase (CYP51) and its G310D mutant (cytochrome P-450SG1). , 1992, The Journal of biological chemistry.
[108] K. Korzekwa,et al. Predicting the cytochrome P450 mediated metabolism of xenobiotics. , 1993, Pharmacogenetics.
[109] A. P. Koley,et al. Conformational modulation of human cytochrome P450 2E1 by ethanol and other substrates: a CO flash photolysis study. , 2000, Biochemistry.
[110] E. Schuetz,et al. Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells. , 1996, Molecular pharmacology.